CE Mark Granted to Corin Group’s Robotic Platform

Corin Group has gained CE Mark approval for its Apollo robotic-assisted surgical platform and ApolloKnee software application. 

CE approval allows Corin Group to commercialise the Apollo robotic-assisted surgical platform and the ApolloKnee procedure across the European Union, broadening the availability of the technology since its 510(k) clearance by the U.S. Food and Drug Administration in November 2023.
 
“ApolloKnee represents a significant leap forward in Total Knee Arthroplasty (TKA). The pre-resection BalanceBot provides an objective, robotic knee balance through the entire range of motion before the surgeon commits to making any bone cuts. This approach gives surgeons the freedom to use any alignment philosophy with a tibia-first or femur-first workflow,” said Dr. Jim Pierrepont, Global Franchise lead at Corin Group.
 
The next-generation Apollo surgical platform is built on a decade of clinical success in robotic-assisted TKA, according to the company. Enhancements include objective pre-resection knee balance, autonomous planning tailored to individual surgeon preferences, a gesture-controlled workflow, robotic-assisted tibial cutting, seamless integration with the CorinConnect surgeon portal, and the ability to support multiple surgical applications.
 
ApolloKnee is designed to go beyond alignment, delivering personalized dynamic balance, executives claim. The solution combines optimal planning, precise implementation, and continuous learning to achieve the forgotten knee.
 
“Attaining CE approval for Apollo is a testament to Corin’s commitment to innovation and excellence,” stated Corin Group CEO Jon Serbousek, who also is senior advisor to parent company Permira. “This approval will enable us to bring our balancing technology to more facilities, transforming the way joint replacements are performed.”

Corin Group is headquartered in Cirencester, United Kingdom.